Citations

Showing 10 of 108104 citations.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Alva, Ajjai , Carlo, Maria I. , Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Michaelson, M. Dror , Mortazavi, Amir , Nandagopal, Lakshminarayanan , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Dwyer, Mary A., Gurski, Lisa A., Motter, Angela D., Anderson, Larry D. , Choueiri, Toni K , Anderson, Larry D , Motzer, Robert J. , Jonasch, Eric W. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , George, Saby , Gore, John L. , Haas, Naomi B , Hancock, Steven Lee , Kapur, Payal , Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Plimack, Elizabeth R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 71-90

10.6004/jnccn.2022.0001 | PMID 34991070 Get It

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma
Sborov, Douglas W. , Hillengaß, Jens , Streiff, Michael B. , Kumar, Shaji , Baljević, Muhamed , Lim, Ming Y , Martin, Thomas G. , Castillo, Jorge J. , Callander, Natalie S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 91-95

10.6004/jnccn.2021.7112 | PMID 34991076 Get It

Venous thromboembolism (VTE) is a major complication in all patients with cancer. Compared with the general population, patients with multiple myeloma (MM) have a 9-fold increase in VTE risk, likely because of their malignancy, its treatments, and other additional patient-related factors. In MM, thromboembolism events tend to occur within 6 months of treatment initiation, regardless of treatment regimen; however, the use of immunomodulatory agents such as thalidomide or lenalidomide, especially in combination with dexamethasone or multiagent chemotherapy, is known to create a significant risk for VTE. Currently, official recommendations for VTE prophylaxis in MM outlined in various national guidelines or multidisciplinary society panels are based on expert opinion, because data from randomized controlled trials are scarce. Large studies which have mainly focused on the efficacy of thromboprophylaxis in patients with cancer at higher risk for VTE either had a very low representation of patients with MM, or excluded them all together, limiting our ability to draw evidence-based conclusions on how to effectively protect MM population from VTE. In this brief perspective, we highlight some of the greatest challenges that have hampered the field concerning the availability of high-quality clinical trial data for the formulation of best VTE prophylaxis strategies in patients with newly diagnosed MM, as well as the rationale for the latest updates in the NCCN Guidelines on this topic.
Neoplastic Cellularity Assessment in Molecular Testing
Devereaux, Kelly A., Souers, Rhona J., Graham, Rondell P., Portier, Bryce P, Surrey, Lea F., Yemelyanova, Anna, Vasalos, Patricia, Trembath, Dimitri G., Moncur, Joel T., Devereaux, Kelly A., Souers, Rhona J., Graham, Rondell P., Portier, Bryce P, Surrey, Lea F., Yemelyanova, Anna, Vasalos, Patricia, Trembath, Dimitri G., Moncur, Joel T.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2022 | Volume: 146 | Issue: 9 | Pages: 1062-1071

10.5858/arpa.2021-0166-cp | PMID 35089997 Get It

Context.— Neoplastic cellularity assessment has become an essential component of molecular oncology testing; however, there are currently no best practice recommendations or guidelines for this potentially variable step in the testing process. Objective.— To describe the domestic and international practices of neoplastic cellularity assessment and to determine how variations in laboratory practices affect neoplastic cellularity assessment accuracy. Design.— Data were derived from 57 US and international laboratories that participated in the 2019 College of American Pathologists Neoplastic Cellularity Proficiency Testing Survey (NEO-B 2019). NEO-B 2019 included 29 laboratory practice questions and 5 images exhibiting challenging histologic features. Participants assessed the neoplastic cellularity of hematoxylin-eosin–stained digital images, and results were compared to a criterion standard derived from a manual cell count. Results.— The survey responses showed variations in the laboratory practices for the assessment of neoplastic cellularity, including the definition of neoplastic cellularity, assessment methodology, counting practices, and quality assurance practices. In some instances, variation in laboratory practice affected neoplastic cellularity assessment performance. Conclusions.— The results highlight the need for a consensus definition and improved standardization of the assessment of neoplastic cellularity. We put forth an initial set of best practice recommendations to begin the process of standardizing neoplastic cellularity assessment.
Lifestyle modifications and complementary treatments for hidradenitis suppurativa
De, Devea R. , Rick, Jonathan W. , Shih, Terri , Hsiao, Jennifer L. , Hsiao, Jennifer L , Alavi, Afsáneh , Shi, Vivian Y.

Mayo Clinic

Dermatological Reviews | January 28, 2022 | Volume: 3 | Issue: 3 | Pages: 126-136

10.1002/der2.117 Get It

AbstractBackgroundHidradenitis suppurativa (HS) is a chronic inflammatory dermatosis with recurrent painful nodules and abscesses affecting the intertriginous areas. Patients often experience a significant negative impact on quality of life from associated pain, discharge, odor, scarring, and social stigma. Even with complex medical regimens, patients may report inadequate disease control. Lifestyle changes and complementary and alternative medicines (CAM) are used by a majority of HS patients. Conventional medicines and lifestyle and CAM modalities strategically incorporated together can increase treatment satisfaction and success.ObjectiveWe aim to highlight lifestyle and CAM treatment modalities to use alongside conventional treatment plans for HS patients.FindingsLifestyle modifications for HS patients include weight loss, reducing skin friction, smoking cessation, and stress reduction. Dietary modifications for HS patients include limiting foods containing dairy, Brewer's yeast, and simple carbohydrates, appropriate caloric reduction, and consuming foods in the Mediterranean diet. The CAM modalities studied in HS are vitamin D, niacinamide, vitamin B12, zinc, and magnesium. Potential CAM modalities for HS include probiotics, cannabinoids, turmeric, bathing regimens, and acupuncture.ConclusionThis review is a guide for clinicians to provide evidence‐based care for HS patients seeking non‐pharmacologic treatment modalities such as weight loss, clothing choices, dietary changes, and use of supplements and complementary medicine. Lifestyle and CAM modalities may be used in parallel with conventional medicines to synergistically improve patient disease outcomes.
Integrating Telehealth Into Neurodevelopmental Assessment: A Model From the Cardiac Neurodevelopmental Outcome Collaborative
Cox, Stephany , Butcher, Jennifer , Sadhwani, Anjali , Sananes, Renée , Blumenfeld, Elizabeth, Cassidy, Adam R. , Cowin, Jessica C, Ilardi, Dawn , Kenowitz, Joslyn, Kroll, Kristin H. , Miller, Thomas A. , Collaborative, from the Telehealth Task Force of the Cardiac Neurodevelopmental Outcome, Cox, Stephany M , Kasparian, Nadine A , Wolfe, Kelly R , Sanz, Jacqueline H. , Kenowitz, Joslyn , Wolfe, Kelly R. , Collaborative, from the Telehealth Task Force of the Cardiac Neurodevelopmental Outcome

Mayo Clinic

Journal of Pediatric Psychology | January 28, 2022 | Volume: 47 | Issue: 6 | Pages: 707-713

10.1093/jpepsy/jsac003 | PMID 35146508 Get It

Abstract Objective In the wake of the COVID-19 pandemic, psychologists were pushed to look beyond traditional in-person models of neurodevelopmental assessment to maintain continuity of care. A wealth of data demonstrates that telehealth is efficacious for pediatric behavioral intervention; however, best practices for incorporating telehealth into neurodevelopmental assessment are yet to be developed. In this topical review, we propose a conceptual model to demonstrate how telehealth can be incorporated into various components of neurodevelopmental assessment. Methods Harnessing existing literature and expertise from a multidisciplinary task force comprised of clinicians, researchers, and patient/parent representatives from the subspecialty of cardiac neurodevelopmental care, a conceptual framework for telehealth neurodevelopmental assessment was developed. Considerations for health equity and access to care are discussed, as well as general guidelines for clinical implementation and gaps in existing literature. Results There are opportunities to integrate telehealth within each stage of neurodevelopmental assessment, from intake to testing, through to follow-up care. Further research is needed to determine whether telehealth mitigates or exacerbates disparities in access to care for vulnerable populations as well as to provide evidence of validity for a wider range of neurodevelopmental measures to be administered via telehealth. Conclusions While many practices are returning to traditional, face-to-face neurodevelopmental assessment services, psychologists have a unique opportunity to harness the momentum for telehealth care initiated during the pandemic to optimize the use of clinical resources, broaden service delivery, and increase access to care for pediatric neurodevelopmental assessment.
Flawed Critique of CLSI Guideline EP05-A2
Ladwig, Paula M. , Vaks, Jeffrey E, Vaks, Jeffrey E.

Mayo Clinic

The Journal of Applied Laboratory Medicine | January 28, 2022 | Volume: 7 | Issue: 3 | Pages: 815-817

10.1093/jalm/jfac007 | PMID 35262679 Get It

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin , Elsedawy, Noura, Faiman, Matthew , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Sborov, Douglas W. , Shain, Kenneth H. , Weber, Donna, Berardi, Ryan A., Kumar, Shaji , Holmberg, Leona , Anderson, Larry D , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Castillo, Jorge J. , Devarakonda, Srinivas , Garfall, Alfred L. , Kang, Yubin , Martin, Thomas G. , Stockerl‐Goldstein, Keith , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 8-19

10.6004/jnccn.2022.0002 | PMID 34991075 Get It

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management
Szuber, Natasha , Elliott, Michelle A. , Tefferi, Ayalew , Elliott, Michelle , Szuber, Natasha

Mayo Clinic

American Journal of Hematology | January 28, 2022 | Volume: 97 | Issue: 4 | Pages: 491-505

10.1002/ajh.26481 | PMID 35089603 Get It

Abstract Disease Overview Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The 2013 seminal discovery of oncogenic driver mutations in colony‐stimulating factor 3 receptor ( CSF3R ) in the majority of patients with CNL not only established its molecular pathogenesis but provided a diagnostic biomarker and rationale for pharmacological targeting. Diagnosis In 2016, the World Health Organization (WHO) recognized activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 10 9 /L comprising >80% neutrophils with <10% circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN. Management There is currently no standard of care for management of CNL, due in large part to the rarity of disease and dearth of formal clinical trials. Most commonly used therapeutic agents include conventional oral chemotherapy (e.g., hydroxyurea), interferon, and Janus kinase (JAK) inhibitors, while hematopoietic stem cell transplant remains the only potentially curative modality. Disease Updates Increasingly comprehensive genetic profiling in CNL, including new data on clonal evolution, has disclosed a complex genomic landscape with additional mutations and combinations thereof driving disease progression and drug resistance. Although accurate prognostic stratification and therapeutic decision‐making remain challenging in CNL, emerging data on molecular biomarkers and the addition of newer agents, such as JAK inhibitors, to the therapeutic arsenal, are paving the way toward greater standardization and improvement of patient care.
Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations
Kimple, Adam J. , Senior, Brent A. , Naureckas, Edward T. , Gudis, David A. , Meyer, Ted A., Hempstead, Sarah E. , Resnick, Helaine E. , Albon, Dana , Barfield, Wayne, Benoit, Margo McKenna , Callard, Eliza, Cofer, Shelagh A. , Downer, Veronica S., Elson, E. Claire , Garinis, Angela C. , Halderman, Ashleigh A. , Hamburger, Lisa, Helmick, Meagan , McCown, Michael , McKinzie, Cameron J. , Phan, Hanna , Rodriguez, Kenneth , Severin, Ashley, Shah, Gopi , Shenoy, Ambika , Sprouse, Brittney , Virgin, Frank W. , Woodworth, Bradford A. , Beswick, Daniel , Cofer, Shelagh, Helmick, Meagan , Woodworth, Bradford A , Gudis, David A , Kimple, Adam J , Beswick, Daniel M. , Hamburger, Lisa, McKinzie, Cameron J. , Rubenstein, Ronald C. , Lee, Stella E.

Mayo Clinic

International Forum of Allergy & Rhinology | January 28, 2022 | Volume: 12 | Issue: 9 | Pages: 1089-1103

10.1002/alr.22974 | PMID 35089650 Get It

Abstract Background Cystic fibrosis (CF) is a multisystem disease that often requires otolaryngology care. Individuals with CF commonly have chronic rhinosinusitis but also present with hearing loss and dysphonia. Given these manifestations of CF, otolaryngologists are frequently involved in the care of patients with CF; however, there is limited consensus on optimal management of sinonasal, otologic, and laryngologic symptoms. Methods The Cystic Fibrosis Foundation convened a multidisciplinary team of otolaryngologists, pulmonologists, audiologists, pharmacists, a social worker, a nurse coordinator, a respiratory therapist, two adults with CF, and a caregiver of a child with CF to develop consensus recommendations. Workgroups developed draft recommendation statements based on a systematic literature review, and a ≥80% consensus was required for acceptance of each recommendation statement. Results The committee voted on 25 statements. Eleven statements were adopted recommending a treatment or intervention, while five statements were formulated recommending against a specific treatment or intervention. The committee recommended eight statements as an option for select patients in certain circumstances, and one statement did not reach consensus. Conclusion These multidisciplinary consensus recommendations will help providers navigate decisions related to otolaryngology consultation, medical and surgical management of CF‐CRS, hearing, and voice in individuals with CF. A collaborative and multidisciplinary approach is advocated to best care for our patients with CF. Future clinical research is needed utilizing standardized, validated outcomes with comprehensive reporting of patient outcome, effects of modulator therapies, and genetic characteristics to help continue to advance care, decrease morbidity, and improve the quality of life for individuals with CF.
Management of eosinophilic esophagitis associated food impaction in Europe and the United States
Schoepfer, Alain , Greuter, Thomas , Biedermann, Luc , Schlag, Christoph , Labenz, Joachim , Auth, Marcus , Chang, Joy W. , Bonis, Peter A, Hirano, Ikuo , Gupta, Sandeep K. , Katzka, David A. , Dellon, Evan S. , Straumann, Alex , Furuta, Glenn T. , Gonsalves, Nirmala , Chang, Joy W , Schreiner, Philipp , Safroneeva, Ekaterina , Bredenoord, Albert J. , Rothenberg, Marc E. , Collins, Margaret H.

Mayo Clinic

Diseases of the Esophagus | January 28, 2022 | Volume: 35 | Issue: 9 | Pages: No page available

10.1093/dote/doac003 | PMID 35088073 Get It

Summary Eosinophilic esophagitis (EoE) is the most common cause of esophageal food impaction (EFI). Approaches to management of EFI due to EoE have not been well characterized. We conducted a web-based survey to understand approaches to management of EFI due to EoE among endoscopists. Questions focused on management of patients from presentation to post-endoscopy follow-up. The survey was administered to a list of eligible candidates provided by societies of gastroenterology. A total of 308 endoscopists completed the questionnaire. The majority (83%) practiced in Europe and treated adults (78%). Most agreed patients should be advised to seek emergency care (66%) within 1 to 2 hours (41% agreement). There was agreement that medications to induce vomiting should be avoided (84%) and that blood tests or imaging studies were usually not required before endoscopy. By contrast, there was more variability in the type of sedation recommended and the need for endotracheal intubation, especially when comparing more experienced with less experienced EoE-endoscopists. Overall, fewer than half (43%) respondents recommended obtaining esophageal biopsies during the initial endoscopy. However, there were significant differences in the proportion who recommended biopsies based on level of EoE-experience (25, 52, 77%, P &lt; 0.001; less vs. moderate vs. very experienced) and comparing pediatric and adult endoscopists (32, vs. 79%, P &lt; 0.001; adult vs. pediatric). There exists heterogeneity among endoscopists in recommendations to manage EFI in patients with EoE. These findings support development of clinical guidelines and new studies to clarify the rationale for best practices. Key summary: Established knowledge—The optimal management of patients with esophageal food impaction due to eosinophilic esophagitis from presentation at the emergency department to postendoscopy care is unclear. New findings—Considerable recommendation variation exists in the management of EFI in patients with EoE. Our findings provide a rationale for the creation of consensus practice guidelines and further study into best practices.